Skip to main content

Table 3 Independence assessment of prognostic model

From: Two precision medicine predictive tools for six malignant solid tumors: from gene-based research to clinical application

 

Univariate analysis

Multivariate analysis

HR

95% CI

P-value

coefficient

HR

95% CI

P-value

Model group

 Gender (male/female)

0.883

0.586–1.33

0.551

− 0.247

0.781

0.508–1.202

0.261

 Age (high/low)

0.591

0.381–0.917

0.018

0.161

1.175

0.765–1.804

0.463

 AJCC stage (IV, III/II, I)

0.323

0.21–0.498

< 0.001

1.196

3.306

1.979–5.522

< 0.001

 Prognostic model (high/low)

6.48

2.037–20.61

< 0.001

1.499

4.476

2.706–7.403

< 0.001

Validation group

 Gender (male/female)

0.993

0.66–1.496

0.975

− 0.089

0.915

0.608–1.379

0.672

 Age (high/low)

0.942

0.627–1.415

0.773

0.712

2.037

1.330–3.120

< 0.001

 AJCC stage (IV, III/II, I)

0.270

0.163–0.448

< 0.001

1.206

3.341

2.185–5.107

< 0.001

 Prognostic model (high/low)

0.210

0.129–0.342

< 0.001

− 1.228

0.293

0.189–0.453

< 0.001

  1. AJCC The American Joint Committee on Cancer, HR hazard ratio, CI confidence interval
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us